03/03/2022
MARCH IS
♋️ The USPSTF (US Preventive Services Task Force) formally endorses age 45 as the starting age for colorectal cancer screening. While this guideline will protect patients in terms of insurance coverage, there are still some uncertainties.
♋️ This recommendation has not been supported by a randomized controlled trial. Furthermore, there will be an increased strain on the healthcare system due to increased demand.
♋️ Implementation of the new recommendations may worsen healthcare disparities in those communities that are already underserved as resources are shifted toward those who have better access to healthcare.
♋️ If we estimate that 4 million turn 50 every year in the USA, now multiply this 5 if we start colonoscopy at age 45. That’s a lot of colonoscopies, doctors, nurses, staff…a lot more stress on a healthcare system already stretched thin. Not to mention the cost!
♋️ Colonoscopy should be offered to high risk individuals (genetic colon cancer syndromes, history of inflammatory bowel disease, strong history of colon adenomas/polyps, family history of colon cancer). In reality, there will be noncompliance in terms of patients who do not want to get screened. It is important to realize that colon cancer screening can be customized. Although colonoscopy is considered the gold standard for colon cancer screening, there are other options:
💩 Stool based testing: for blood (FIT test annually) or stool DNA (MTsDNA–MultiTarget Stool DNA, AKA Cologuard (every one to 3 years)
🧬 Blood test: Septin 9 blood test is newer but not currently endorsed in colorectal cancer screening guidelines. Controlled trials are currently ongoing but early data demonstrated 48% sensitivity for cancer detection.